acromegaly
ACROMEGALY
Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.

Surgical Intervention

Surgical intervention is the 1st-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure

Patients not Eligible for Surgical Treatment

  • Medically unstable condition
  • Patients with airway difficulties and are at high risk for anesthetic complications
  • Major systemic manifestations of acromegaly:
    • Cardiomyopathy
    • Severe hypertension
    • Uncontrolled diabetes mellitus

Goals of Surgical Treatment:

  • To decrease tumor burden, and cure if possible, with preservation of normal pituitary function
  • To reduce mass effect of macroadenomas on remaining normal pituitary gland tissues, the optic chiasm or nerves, and other surrounding structures
  • To rapidly lower or reduce growth hormone and insulin-like growth factor-I levels, control or prevent progression of disease, and relieve associated comorbidities

Transsphenoidal Surgery

  • Treatment of choice for all patient with microadenomas and or all patients who have macroadenomas with associated mass effect
    • In patients with macroadenomas without mass effects, and low likelihood of surgical cure, surgical debulking may improve response to subsequent medical therapy
    • Primary medical therapy alone has also been advocated for those with macroadenomas not likely to be cured by surgery
  • Transnasal endoscopic procedures have shown improved patients satisfaction and shorter hospital stay compared with traditional sublabial procedures, without compromising surgical success
  • In noninvasive macroadenomas, biochemical control with normalization of insulin-like growth factor-I occurs in 40-68% of the patients
  • In intrasellar microadenomas, surgery provides biochemical control and normalization of insulin-like growth factor-I in 75-95% of patients
  • Surgery requires expertise to achieve control rates
  • Some clinicians have found benefits with the use of somatostatin receptor ligands (SRL) prior to surgery
    • Some have claimed pretreatment with SRLs have improved normalization of growth hormone and insulin-like growth factor-I after surgery and shorten the duration of hospital stay
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tee Hoi Poh, 26 Sep 2018
Stool-based colorectal cancer (CRC) screening should be the preferred method of CRC screening in Malaysia, according to Dato Dr Muhammad Radzi Abu Hassan, the Head of Gastroenterology Services in Ministry of Health, Malaysia, who presented the Malaysian experience on CRC screening at the Annual Scientific Meeting of the Society of Gastroenterology and Hepatology (GUT) 2018 held recently in Penang.
Jackey Suen, 26 Nov 2018

Linagliptin has no impact on cognitive decline when given on top of standard of care in patients with type 2 diabetes mellitus (T2DM), a CARMELINA substudy has shown.